<DOC>
	<DOCNO>NCT01892020</DOCNO>
	<brief_summary>This trial conduct Asia . The aim trial investigate efficacy safety biphasic insulin aspart 50 ( BIAsp 50 ) twice daily versus biphasic human insulin 50 ( BHI 50 ) twice daily , combination metformin , Chinese subject type 2 diabetes mellitus .</brief_summary>
	<brief_title>Investigating Efficacy Safety Biphasic Insulin Aspart 50 Twice Daily Versus Biphasic Human Insulin 50 Twice Daily Both Combination With Metformin Chinese Subjects With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<criteria>Type 2 diabetes mellitus ( diagnose clinically ) least 12 month Currently treat premixed human insulin 50 BID least 3 month prior screen visit ( Visit 1 ) Currently treat unchanged total daily dose least 1500 mg metformin maximum tolerate dose least 1000 mg/day metformin least 2 month prior screen visit Glycosylated haemoglobin ( HbA1c ) 7.0 % 9.0 % ( inclusive ) ( central laboratory ) Treatment insulin secretagogue , alfaglucosidase inhibitor , thiazolidinedione ( TZD ) , dipeptidyl peptidase4 ( DPP4 ) inhibitor Glucagonlike peptide1 ( GLP1 ) receptor agonist within last 3 month prior screen Previous use insulin premixed human insulin 50 BID within 3 month prior Visit 1 Previous use insulin intensification treatment ( premixed insulin thrice daily , basal bolus regimen , continuous subcutaneous insulin infusion ( CSII ) ) 14 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>